Capricor: I Rate It A Buy After Stress-Testing The Sell Thesis [Seeking Alpha]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Seeking Alpha
Recent HOPE-3 data disclosures address most prior concerns about primary and cardiac endpoints, reducing trial-related risks. Key remaining risks include commercial disputes with NS Pharma/Nippon Shinyaku and limited initial manufacturing capacity. Valuation is not aggressive given a $600k net annual price and 2,500 US peak patients, but downside remains if the FDA issues a CRL or narrows the label. Looking for a portfolio of ideas like this one? Members of The Total Pharma Tracker get exclusive access to our subscriber-only portfolios. Learn More » Jonathan Kitchen/DigitalVision via Getty Images Every recent article on Seeking Alpha about Capricor ( CAPR ) is a Buy or a Hold - except that one Sell article from December. So I checked out the article, and I found the argument More on my IG service About the TPT service Thanks for reading. At the Total Pharma Tracker , we offer most of the following:- For investors requiring hands-on support, our in-house experts go t
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Capricor Therapeutics (CAPR) was upgraded by LADENBURG THALM/SH SH to "strong-buy".MarketBeat
- Capricor's Positive 5-Year Data For DMD Treatment Comes With A Regulatory Catch – CAPR Stock Slides 11% [Yahoo! Finance]Yahoo! Finance
- Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy [Yahoo! Finance]Yahoo! Finance
- Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular DystrophyGlobeNewswire
- Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual ConferenceGlobeNewswire
CAPR
Earnings
- 5/12/26 - Miss
CAPR
Analyst Actions
- 5/13/26 - HC Wainwright
CAPR
Sec Filings
- 6/29/26 - Form 4
- 6/29/26 - Form 4
- 6/26/26 - Form 8-K
- CAPR's page on the SEC website